These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 23204382)

  • 1. A case series of patients with severe pulmonary hypertension receiving an implantable pump for intravenous prostanoid therapy.
    Ewert R; Halank M; Bruch L; Ghofrani HA
    Am J Respir Crit Care Med; 2012 Dec; 186(11):1196-8. PubMed ID: 23204382
    [No Abstract]   [Full Text] [Related]  

  • 2. Procedural safety of a fully implantable intravenous prostanoid pump for pulmonary hypertension.
    Richter MJ; Ewert R; Warnke C; Gall H; Classen S; Grimminger F; Mayer E; Seeger W; Ghofrani HA
    Clin Res Cardiol; 2017 Mar; 106(3):174-182. PubMed ID: 27670656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The "bouncing" catheter.
    Malaczynska-Rajpold K; Kurzyna M; Koteja A; Torbicki A; Mularek-Kubzdela T
    Cardiol J; 2016; 23(5):552-553. PubMed ID: 27723062
    [No Abstract]   [Full Text] [Related]  

  • 4. Intravenous treprostinil infusion via a fully implantable pump for pulmonary arterial hypertension.
    Ewert R; Richter MJ; Steringer-Mascherbauer R; Grünig E; Lange TJ; Opitz CF; Warnke C; Ghofrani HA
    Clin Res Cardiol; 2017 Oct; 106(10):776-783. PubMed ID: 28429083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversible pulmonary hypertension in a patient treated with protacyclin.
    Engel PJ; Baughman R; Johnson H; Kereikes DJ
    J Invasive Cardiol; 2004 Nov; 16(11):660-2. PubMed ID: 15550741
    [No Abstract]   [Full Text] [Related]  

  • 6. Effectiveness of transition from intravenous epoprostenol to oral/inhaled targeted pulmonary arterial hypertension therapy in pediatric idiopathic and familial pulmonary arterial hypertension.
    Melnick L; Barst RJ; Rowan CA; Kerstein D; Rosenzweig EB
    Am J Cardiol; 2010 May; 105(10):1485-9. PubMed ID: 20451700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Totally Implantable IV Treprostinil Therapy in Pulmonary Hypertension Assessment of the Implantation Procedure.
    Waxman AB; McElderry HT; Gomberg-Maitland M; Burke MC; Ross EL; Bersohn MM; Pangarkar SS; Tarver JH; Zwicke DL; Feldman JP; Chakinala MM; Frantz RP; Thompson GB; Torres F; Rauck RL; Clagg K; Durst L; Li P; Morris M; Southall KL; Peterson L; Bourge RC
    Chest; 2017 Dec; 152(6):1128-1134. PubMed ID: 28583617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of transition from systemic prostanoids to inhaled treprostinil in pulmonary arterial hypertension.
    de Jesus Perez VA; Rosenzweig E; Rubin LJ; Poch D; Bajwa A; Park M; Jain M; Bourge RC; Kudelko K; Spiekerkoetter E; Liu J; Hsi A; Zamanian RT
    Am J Cardiol; 2012 Nov; 110(10):1546-50. PubMed ID: 22853986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subcutaneous implantation of a new intravenous pump system for prostacyclin treatment in patients with pulmonary arterial hypertension.
    Desole S; Velik-Salchner C; Fraedrich G; Ewert R; Kähler CM
    Heart Lung; 2012; 41(6):599-605. PubMed ID: 22920608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of switching from epoprostenol to IV treprostinil on treatment satisfaction and quality of life in patients with pulmonary hypertension.
    Minai OA; Parambil J; Dweik RA; Davila GH; Peterson L; Rollins KD; Chen H
    Respir Med; 2013 Mar; 107(3):458-65. PubMed ID: 23266038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma brain natriuretic peptide as a parameter to assess efficacy of continuous intravenous infusion of prostacyclin (epoprostenol) to treat severe primary pulmonary hypertension: a case report.
    Wakaumi M; Shiga T; Nozaki K; Fujiu K; Shimaya K; Ishizuka N; Matsuda N; Kasanuki H
    Heart Vessels; 2000; 15(3):144-6. PubMed ID: 11289503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transition from parenteral to oral treprostinil in pulmonary arterial hypertension.
    Chakinala MM; Feldman JP; Rischard F; Mathier M; Broderick M; Leedom N; Laliberte K; White RJ
    J Heart Lung Transplant; 2017 Feb; 36(2):193-201. PubMed ID: 27469018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term experience after transition from parenteral prostanoids to oral agents in patients with pulmonary hypertension.
    Diaz-Guzman E; Heresi GA; Dweik RA; Minai OA
    Respir Med; 2008 May; 102(5):681-9. PubMed ID: 18280130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Moderate-term effect of epoprostenol on severe portopulmonary hypertension.
    Kato H; Katori T; Nakamura Y; Kawarasaki H
    Pediatr Cardiol; 2003; 24(1):50-3. PubMed ID: 12574979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An implantable pump Lenus pro® in the treatment of pulmonary arterial hypertension with intravenous treprostinil.
    Kurzyna M; Małaczyńska-Rajpold K; Koteja A; Pawlak A; Chrzanowski Ł; Furdal M; Gąsior Z; Jacheć W; Sobkowicz B; Norwa J; Mularek-Kubzdela T; Torbicki A
    BMC Pulm Med; 2017 Dec; 17(1):162. PubMed ID: 29195500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A 50-year-old woman with dyspnea, lower extremity edema, and volume loss of the right hemithorax.
    Shostak E; Sarwar A
    Chest; 2009 Aug; 136(2):628-632. PubMed ID: 19666764
    [No Abstract]   [Full Text] [Related]  

  • 17. [The first LENUS pro® pump implantation in Poland in patient with pulmonary hypertension].
    Pawlak A; Koteja A; Starska A; Kurzyna M; Gil RJ
    Kardiol Pol; 2016; 74(3):300. PubMed ID: 27004544
    [No Abstract]   [Full Text] [Related]  

  • 18. Patient safety challenges in treprostinil therapy.
    Roncesvalles A; Lee FW; Camamo J; Priestley G
    Medsurg Nurs; 2008 Apr; 17(2):101-6. PubMed ID: 18517170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pulmonary arterial hypertension: classification and therapy with a focus on prostaglandin analogs.
    Papierniak ES; Lowenthal DT; Mubarak K
    Am J Ther; 2012 Jul; 19(4):300-14. PubMed ID: 21642835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension.
    Gomberg-Maitland M; Tapson VF; Benza RL; McLaughlin VV; Krichman A; Widlitz AC; Barst RJ
    Am J Respir Crit Care Med; 2005 Dec; 172(12):1586-9. PubMed ID: 16151039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.